The dynamic mitral valve is prone to three diseases, which are known as mitral stenosis (MS), mitral regurgitation (MR), and mitral valve prolapse (MVP). As a key anatomic and functional structure, advanced disease of this valve may lead to complications such as heart failure and death [1].

MS is commonly caused by rheumatic fever, which is rare in industrialized countries but still prevalent in developing regions. The disease presents in young adults usually in the third or fourth decade with symptoms such as fatigue, palpitations, chest pain, hemoptysis [2]. When MS progresses, the patient may experience dyspnea on exertion, orthopnea, as well as paroxysmal nocturnal dyspnea [3]. Among the clinical features are jugular vein distension and a displaced apical impulse. On auscultation, there is a loud S1 (first heart sound), split S2 (second heart sound), an opening snap, and a diastolic rumble.

MR typically develops as a consequence of aging mechanisms, ischemic disease, rheumatic fever, or prolapse [2] [4]. There are two forms of MR, which are acute (rare) and chronic. Often the result of valvular infection, the presentation of acute MR mimics that of acute heart failure. However, chronic MR evolves gradually and may be asymptomatic in the early stages. Features include fatigue, dyspnea, palpitations, and so forth. Auscultation findings include an apical holosystolic murmur with a soft S1, split S2, and possibly a third heart sound (S3).

MVP is found in up to 3% of the population [5] and is more predominant in young women [2]. While many individuals with prolapse do not exhibit symptoms, some will have fatigue, dizziness, dyspnea, palpitations, chest pain, anxiety, and presyncope. The palpitations may be triggered by emotional stress. The hallmark murmur is a mid-to-late systolic click.

Individuals with a clinical presentation suggestive of mitral valve disease warrant a thorough workup consisting of the patient and family history, physical exam including auscultation [2], and the appropriate studies.

Laboratory tests

The workup should include a complete blood count (CBC) a complete metabolic panel (CMP).

Imaging

Echocardiography is a critical component of the assessment since it is noninvasive, accessible, and provides information for diagnosis and monitoring of the disease [6]. This modality is sensitive and specific for identifying MS [7] and is the key for diagnosing MR and MVP [8]. This study also allows the clinician to determine the etiology and stage of the valvular abnormality and functionality and size of the atria.

Transthoracic echocardiogram (TTE) reveals mobility, calcification, and thickening of the valve [9]. Moreover, real-time 3-dimensional transesophageal echocardiography (TEE), which is superior to TTE, offers excellent images of the mitral valve [10]. Very importantly, TEE is very beneficial in cases suggestive of endocarditis or presence of thrombi.

Chest radiography is another important investigative study. In patients with MS, a chest X-ray will likely display calcification of the mitral valve, left atrial enlargement, interstitial edema, and prominent pulmonary vasculature. In patients with chronic MR, chest X-ray findings may include left ventricular and left atrial enlargement, and evidence of heart failure such as pulmonary congestion. Similar observations are found in patients with MVP associated with MR.

Other imaging tests such as ventriculography and cardiac magnetic resonance imaging (MRI) may be utilized to measure the regurgitation.

Electrocardiography (EKG)

An EKG is obtained in all patients with cardiac complaints. A typical finding in patients with advanced MS is atrial fibrillation. Other remarkable features include prolonged P wave in lead II, which is indicative of left atrial hypertrophy. Features associated with chronic MR are left ventricular and left atrial hypertrophy, and ST segment changes in lateral leads. Additionally, there are P wave abnormalities in various leads. Occasionally, MVP is associated with benign arrhythmias.

Procedures

Cardiac catheterization is performed selectively prior to surgery. Also, stress EKG is used periodically to monitor MR.

Treatment for Mitral Valve Disease depends on the severity of the condition and the symptoms presented. Mild cases may only require regular monitoring and lifestyle changes, such as diet and exercise modifications. Medications can help manage symptoms and prevent complications. In more severe cases, surgical interventions may be necessary. These can include mitral valve repair, where the existing valve is fixed, or mitral valve replacement, where the damaged valve is replaced with a mechanical or biological valve.

The prognosis for individuals with Mitral Valve Disease varies based on the type and severity of the condition, as well as the treatment received. With appropriate management, many patients can lead normal, active lives. However, untreated or severe cases can lead to complications such as heart failure, atrial fibrillation, or pulmonary hypertension. Regular follow-up with a healthcare provider is crucial to monitor the condition and adjust treatment as needed.

Mitral Valve Disease can result from various causes. Mitral valve stenosis is often caused by rheumatic fever, a complication of untreated strep throat. Mitral valve regurgitation can be due to age-related changes, heart attacks, or conditions like mitral valve prolapse, where the valve's leaflets bulge into the left atrium. Congenital heart defects, infections, and certain connective tissue disorders can also contribute to MVD.

Mitral Valve Disease is a common heart condition, particularly in older adults. The prevalence increases with age, and it is more common in women than men. Rheumatic heart disease, a significant cause of mitral stenosis, is more prevalent in developing countries. In contrast, degenerative mitral regurgitation is more common in developed countries due to longer life expectancies and better management of risk factors.

The pathophysiology of Mitral Valve Disease involves changes in the structure and function of the mitral valve. In mitral stenosis, the valve leaflets thicken and fuse, restricting blood flow from the left atrium to the left ventricle. In mitral regurgitation, the valve fails to close completely, allowing blood to leak backward into the left atrium. These changes can lead to increased pressure in the heart and lungs, eventually causing heart enlargement and reduced cardiac output.

Preventing Mitral Valve Disease involves managing risk factors and underlying conditions. For rheumatic heart disease, prompt treatment of strep throat with antibiotics is crucial. Maintaining a healthy lifestyle, including regular exercise, a balanced diet, and avoiding smoking, can reduce the risk of degenerative valve disease. Regular medical check-ups can help detect early signs of valve problems, allowing for timely intervention.

Mitral Valve Disease encompasses a range of conditions affecting the mitral valve, leading to impaired blood flow in the heart. Symptoms can vary widely, and diagnosis typically involves imaging tests like echocardiograms. Treatment ranges from lifestyle changes and medications to surgical interventions, depending on the severity. Understanding the causes and risk factors can aid in prevention and management, improving the prognosis for many patients.

If you have been diagnosed with Mitral Valve Disease, it's important to understand your condition and treatment options. Regular follow-ups with your healthcare provider are essential to monitor your heart health. Adopting a heart-healthy lifestyle, including a balanced diet, regular exercise, and avoiding tobacco, can help manage your condition. Be aware of your symptoms and report any changes to your doctor promptly. With proper care, many individuals with MVD can lead fulfilling lives.

1. Levine RA, Hagége AA, Judge DP, et al. Mitral valve disease—morphology and mechanisms. Nat Rev Cardiol. 2015;12(12):689-710.
2. Turi ZG. Mitral Valve Disease. Circulation. 2004;109(6):e38-41.
3. Carabello BA. Modern Management of Mitral Stenosis. Circulation. 2005;112(3):432-437.
4. Enriquez-Sarano M, Schaff HV, Frye RL. Mitral regurgitation: what causes the leakage is fundamental to the outcome of valve repair. Circulation. 2003;108(3):253-6.
5. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1–7.
6. Hung JW, Tan TC. Echocardiography in mitral valve disease. Preface. Cardiol Clin. 2013;31(2):ix-x.
7. Wunderlich NC, Beigel R, Siegel RJ. Management of mitral stenosis using 2D and 3D echo-Doppler imaging. JACC Cardiovasc Imaging. 2013;6(11):1191-205.
8. Dal-Bianco JP, Levine RA. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography. Cardiol Clin. 2013;31(2):151–164.
9. Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol. 1998;23(3):125-92. Review.
10. Schlosshan D, Aggarwal G, Mathur G, Allan R, Cranney G. Real-time 3D transesophageal echocardiography for the evaluation of rheumatic mitral stenosis. JACC Cardiovasc Imaging. 2011;4(6):580-8.